4Ardizzoni A,Tjan-Heijnen VC,Postmus PE,et al; European Organization for Research and Treatment of Cancer-Lung Cancer Group.Standard versus intensified chemotherapy with granulocyte colonystimulating factor support in small-cell lung cancer:a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase Ⅲ Trial08923.J Clin Oncol,2002,20(19):3947-3955.
5Kerbel RS,Klement G,Pritchard KI,et al.Continuous low-dose anti-angiogenic/metronomic chemotherapy:from the research laboratory into the oncology clinic.Ann Oncol,2002,13(1):12-15.
6Arriagada R,Le Chevalier T,Pignon JP,et al.Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.N Engl J Med,1993,329(25):1848-1852.
7Samantas E,Skarlos DV,Pectasides D,et al.Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer.Lung Cancer,1999,23(2):159-168.
8Fujimoto K,Harada T,Watanabe K.Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction.Nippon Ronen Igakkai Zasshi,2005,42(4):453-456.
9Nakamura Y,Kunitoh H,Kubota K,et al.Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinumbased chemotherapy.Am J Clin Oncol,2003,26(5):459-464.
10Petrioli R,Pozzessere D,Messinese S,et al.Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens.Lung Cancer,2003,39(1):85-89.
2Bepler G. Ten best readings relating to lung cancer [J]. Cancer Control, 2003,10(4) :334-335.
3Simon GR. Ten best readings on lung cancer[J]. Cancer Control,2001,8(4): 352-353.
4Alberts WM. Ten best readings on lung cancer [J]. CancerControl, 2000,7 ( 1 ): 65-66.
5Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res, 2004,64 ( 11 ) : 3994-4000.
6Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol,2001,19(4):1195-1206.
7Tanaka F, Oyanagi H, Takenaka K, et al. Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer. Cancer Res,2003,63(20) : 6791-6794.
8Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma,serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res,2000,60(11): 2898-2905.
9Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res,2002,62(23): 6938 6943.
10Drevs J, Fakler J, Eisele S, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res,2004,24(3a): 1759-1763.
5Wieland D, Hirth V. Comprehensive geriatric assessment[J], Cancer Control, 2003,10(6) :454 -462.
6Thrasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to cvanluate the response to treatment in solid tumors[J].Natl Cancer lnst,2000, 92(3) : 205-216.
7Socinski M A, Croweu R, Hensing T E, et al. Treatment of non- small cell lung cancer, stage Ⅳ: ACCP evidence-based clinical practive guidelines (2nd edition)[J]. Chest, 2007, 7(5): 2779-2899.
8Nakamura Y, Kunitoh H, Kubota K, et al. Retrospective analysis of safety and efficacy of low - dose docetaxel 60mg/m2 in advanced non - small cell lung cancer patients previously treated with plati- num based chenmotherapy [ J ]. Am J Clin Oncol,2003,26 (5) :459 -464.
9Gridelli C. The ELVIS trial : A phase III study of single - agent vi- norelbine as first - line treatment in elder patients with advanced non - small cell lung cancer. Elderly Lung Cancer Vinorelbine Ital- ian Study[J]. Oncologist,2001,6( 1 ) :4.
10Ffrvida JL, Vazquez S, Grand C, et al. Oral vinorelbine ( NVBO ) and gemcitabine ( GEM ) in eider patients with advanced non - small - cell lung cancer( NSCLC ) : A phase II study conducted by the Galician Lung Cancer Group ( GLCG ) [ J ]. J Clin Oncol, 2008,26(15S) :19068.
